Literature DB >> 24675088

An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.

Laura Cove-Smith1, Neil Woodhouse2, Adam Hargreaves3, Jason Kirk3, Susan Smith3, Sally A Price3, Melanie Galvin3, Catherine J Betts3, Simon Brocklehurst3, Alison Backen4, John Radford5, Kim Linton5, Ruth A Roberts3, Matthias Schmitt6, Caroline Dive4, Jonathan D Tugwood4, Paul D Hockings7, Howard R Mellor8.   

Abstract

Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or functional indices of early damage, which would allow monitoring and intervention, are lacking. In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity. Hannover Wistar rats were dosed with 1.25 mg/kg DOX weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction. In summary, subcellular cardiomyocyte degeneration was the earliest marker, followed by progressive functional decline and histopathological manifestations. Myocardial contrast enhancement and elevations in cTnI occurred later. However, all indices predated "clinical" LV dysfunction and thus warrant further evaluation as predictive biomarkers.
© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  anthracycline; cardiac MRI; cardiotoxicity; chemotherapy; doxorubicin; ejection fraction

Mesh:

Substances:

Year:  2014        PMID: 24675088     DOI: 10.1093/toxsci/kfu057

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  16 in total

1.  Cardiac Atrophy and Heart Failure In Cancer.

Authors:  Mark Sweeney; Angela Yiu; Alexander R Lyon
Journal:  Card Fail Rev       Date:  2017-04

2.  Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.

Authors:  Quanyuan Wan; Zihua Zeng; Jianjun Qi; Zhenghu Chen; Xiaohui Liu; Youli Zu
Journal:  Mol Ther       Date:  2022-02-08       Impact factor: 12.910

Review 3.  The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges.

Authors:  Carolyn J Park; Mary E Branch; Sujethra Vasu; Giselle C Meléndez
Journal:  J Cardiovasc Transl Res       Date:  2020-04-04       Impact factor: 4.132

4.  TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy.

Authors:  Tsukasa Shimauchi; Takuro Numaga-Tomita; Tomoya Ito; Akiyuki Nishimura; Ryosuke Matsukane; Sayaka Oda; Sumio Hoka; Tomomi Ide; Norimichi Koitabashi; Koji Uchida; Hideki Sumimoto; Yasuo Mori; Motohiro Nishida
Journal:  JCI Insight       Date:  2017-08-03

5.  Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts.

Authors:  Scott P Levick; David R Soto-Pantoja; Jianli Bi; W Gregory Hundley; Alexander Widiapradja; Edward J Manteufel; Tancia W Bradshaw; Giselle C Meléndez
Journal:  Heart Lung Circ       Date:  2018-09-02       Impact factor: 2.975

Review 6.  Cardiotoxicity in HER2-positive breast cancer patients.

Authors:  Diana Gonciar; Lucian Mocan; Alexandru Zlibut; Teodora Mocan; Lucia Agoston-Coldea
Journal:  Heart Fail Rev       Date:  2021-01-06       Impact factor: 4.214

7.  The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity.

Authors:  Beshay N Zordoky; M Judith Radin; Lois Heller; Anthony Tobias; Ilze Matise; Fred S Apple; Sylvia A McCune; Leslie C Sharkey
Journal:  Cardiooncology       Date:  2016-03-15

8.  Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Authors:  Robin Chung; Angshuman Maulik; Ashraf Hamarneh; Daniel Hochhauser; Derek J Hausenloy; J Malcolm Walker; Derek M Yellon
Journal:  Clin Cardiol       Date:  2016-01-25       Impact factor: 2.882

9.  The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity.

Authors:  Edoardo Lazzarini; Carolina Balbi; Paola Altieri; Ulrich Pfeffer; Elisa Gambini; Marco Canepa; Luigi Varesio; Maria Carla Bosco; Domenico Coviello; Giulio Pompilio; Claudio Brunelli; Ranieri Cancedda; Pietro Ameri; Sveva Bollini
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

Review 10.  Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury.

Authors:  M J Cross; B R Berridge; P J M Clements; L Cove-Smith; T L Force; P Hoffmann; M Holbrook; A R Lyon; H R Mellor; A A Norris; M Pirmohamed; J D Tugwood; J E Sidaway; B K Park
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.